O'Brien Monaghan Stephanie's Insider Trades & SAST Disclosures
O'Brien Monaghan Stephanie's most recent trade in Apellis Pharmaceuticals Inc was a trade of 11,199 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 1, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern O'Brien Monaghan Stephanie.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals Inc | Stephanie Monaghan O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 11,199 | 11,199 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Stephanie Monaghan O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 6,267 | 17,705 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | O'Brien Monaghan Stephanie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 5,748 | 5,748 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | O'Brien Stephanie Monaghan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 3,341 | 11,438 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Stephanie Monaghan O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2023 | 7,441 | 7,441 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Stephanie Monaghan O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2023 | 3,867 | 8,097 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Stephanie Monaghan O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 8,554 | 8,554 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Stephanie Monaghan O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 4,230 | 4,230 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Stephanie Monaghan O'Brien | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2021 | 27,600 | 27,600 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges